STOCK TITAN
  1. Home
  2. Sec-filings
  3. ROIV
  4. [Form 4] Roivant Sciences Ltd. Insider Trading Activity

Roivant Sciences Stock Under Pressure as 10% Owner Dumps Million+ Shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vivek Ramaswamy, a 10% owner of Roivant Sciences, reported significant insider sales transactions in June 2025. The transactions include:

  • June 18, 2025: Sold 565,266 common shares at an average price of $11.45 (range: $11.41-$11.53)
  • June 20, 2025: Sold 577,007 common shares at an average price of $11.46 (range: $11.45-$11.54)

Following these transactions, Ramaswamy maintains direct ownership of 37,284,108 common shares and indirect beneficial ownership of 13,357,857 shares through spousal holdings. The total value of shares sold was approximately $13.1 million. These sales represent a notable reduction in his direct holdings but maintain his position as a significant shareholder.

Positive

  • None.

Negative

  • Major insider selling: 10% owner Vivek Ramaswamy sold approximately 1.14 million shares worth ~$13.1 million over two days at prices around $11.45-11.46
  • The large sale represents a significant disposition of shares by a major shareholder, potentially signaling reduced confidence in the company's near-term prospects
Insider Ramaswamy Vivek
Role 10% Owner
Sold 1,142,273 shs ($13.08M)
Type Security Shares Price Value
Sale Common Shares 577,007 $11.46 $6.61M
Sale Common Shares 565,266 $11.45 $6.47M
holding Common Shares -- -- --
Holdings After Transaction: Common Shares — 37,284,108 shares (Direct); Common Shares — 13,357,857 shares (Indirect, Spousal)
Footnotes (1)
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.41 to $11.53, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.45 to $11.54, inclusive. Represents the quantity of shares held indirectly only.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ramaswamy Vivek
(Last) (First) (Middle)
C/O STEVE ROBERTS
853 NEW JERSEY AVE., SUITE 200-231
(Street)
WASHINGTON DC 20003
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 06/18/2025 S 565,266 D $11.45(1) 37,861,115 D
Common Shares 06/20/2025 S 577,007 D $11.46(2) 37,284,108 D
Common Shares 13,357,857(3) I Spousal
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.41 to $11.53, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.45 to $11.54, inclusive.
3. Represents the quantity of shares held indirectly only.
By: /s/ Stephen Roberts, as Attorney-in-Fact for Vivek Ramaswamy 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many ROIV shares did Vivek Ramaswamy sell in June 2025?

Vivek Ramaswamy sold a total of 1,142,273 shares of ROIV common stock across two transactions: 565,266 shares on June 18, 2025, and 577,007 shares on June 20, 2025.

What was the selling price of ROIV shares in Ramaswamy's June 2025 transactions?

The shares were sold at weighted average prices of $11.45 (June 18) and $11.46 (June 20). Specifically, the June 18 sales ranged from $11.41 to $11.53 per share, while the June 20 sales ranged from $11.45 to $11.54 per share.

How many ROIV shares does Vivek Ramaswamy still own after the June 2025 sales?

After the reported transactions, Vivek Ramaswamy directly owns 37,284,108 shares of ROIV common stock. Additionally, he indirectly owns 13,357,857 shares through spousal ownership, for a total beneficial ownership of 50,641,965 shares.

What is Vivek Ramaswamy's relationship to Roivant Sciences (ROIV)?

According to the Form 4 filing, Vivek Ramaswamy is a 10% Owner of Roivant Sciences Ltd. (ROIV), indicating he holds a significant ownership stake in the company.